Moors & Cabot Inc. lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 118,073 shares of the company’s stock after selling 345 shares during the period. Johnson & Johnson comprises about 1.3% of Moors & Cabot Inc.’s investment portfolio, making the stock its 8th biggest position. Moors & Cabot Inc.’s holdings in Johnson & Johnson were worth $19,543,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Nwam LLC increased its stake in Johnson & Johnson by 25.7% in the second quarter. Nwam LLC now owns 33,807 shares of the company’s stock valued at $5,596,000 after acquiring an additional 6,916 shares during the last quarter. Checchi Capital Advisers LLC increased its stake in Johnson & Johnson by 4.5% in the second quarter. Checchi Capital Advisers LLC now owns 35,054 shares of the company’s stock valued at $5,802,000 after acquiring an additional 1,509 shares during the last quarter. Cetera Advisors LLC increased its stake in Johnson & Johnson by 2.5% in the second quarter. Cetera Advisors LLC now owns 149,625 shares of the company’s stock valued at $24,766,000 after acquiring an additional 3,682 shares during the last quarter. Meitav Investment House Ltd. increased its stake in Johnson & Johnson by 2.6% in the second quarter. Meitav Investment House Ltd. now owns 8,361 shares of the company’s stock valued at $1,369,000 after acquiring an additional 210 shares during the last quarter. Finally, King Wealth increased its stake in Johnson & Johnson by 1.6% in the second quarter. King Wealth now owns 53,043 shares of the company’s stock valued at $8,780,000 after acquiring an additional 848 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on JNJ. Wells Fargo & Company reduced their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Royal Bank of Canada began coverage on Johnson & Johnson in a research note on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price objective on the stock. Barclays raised their price objective on Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research note on Thursday, October 12th. Morgan Stanley reduced their price objective on Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 18th. Finally, Raymond James reduced their price objective on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 18th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $169.19.
Johnson & Johnson Stock Performance
Shares of JNJ opened at $149.91 on Tuesday. The company has a 50-day simple moving average of $154.52 and a two-hundred day simple moving average of $160.29. The firm has a market capitalization of $360.88 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58. Johnson & Johnson has a one year low of $144.95 and a one year high of $181.04. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.14. The business had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. On average, analysts anticipate that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is presently 35.34%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Safeguard your portfolio with these three bargain stocks
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Membership clubs gain leverage for the consumer rebound
- Are Stock Buybacks Good for the Average Investor?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.